首页> 外文期刊>Journal of chemical information and modeling >LiSiCA: A Software for Ligand-Based Virtual Screening and Its Application for the Discovery of Butyrylcholinesterase Inhibitors
【24h】

LiSiCA: A Software for Ligand-Based Virtual Screening and Its Application for the Discovery of Butyrylcholinesterase Inhibitors

机译:LiSiCA:基于配体的虚拟筛选软件及其在丁酰胆碱酯酶抑制剂发现中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

We developed LiSiCA (ligand similarity using clique algorithm) ligand-based virtual screening software that uses a fast maximum clique algorithm to find two- and three-dimensional similarities between pairs of molecules and applied it to the discovery of novel potent butyrylcholinesterase inhibitors. LiSiCA, which runs in parallel on multiple processor cores, was successfully tested on the Database of Useful Decoys Enhanced, to evaluate its ability to discriminate active molecules from decoys. We then applied LiSiCA for the discovery of novel inhibitors of human butyrylcholinesterase, a promising anti-Alzheimer target, using a known inhibitor as the reference compound. We demonstrated that LiSiCA is capable of finding potent nanomolar inhibitors, whose scaffolds differed from the reference compound, thus proving its ability for scaffold hopping and usefulness in drug discovery.
机译:我们开发了基于LiSiCA(使用团簇算法的配体相似性)基于配体的虚拟筛选软件,该软件使用快速最大团簇算法来查找分子对之间的二维和三维相似性,并将其应用于新型有效的丁酰胆碱酯酶抑制剂的发现。在多个处理器内核上并行运行的LiSiCA已在增强的有用诱饵数据库中成功测试,以评估其区分诱饵中的活性分子的能力。然后,我们将LiSiCA应用于人类丁酰胆碱酯酶的新型抑制剂的发现,这是一种有前途的抗阿尔茨海默氏病靶标,使用已知的抑制剂作为参考化合物。我们证明了LiSiCA能够发现有效的纳摩尔抑制剂,其支架与参考化合物不同,从而证明了其用于支架跳跃的能力以及在药物发现中的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号